Antileishmanial and Antitrypanosomes Drugs for the Current Century

被引:0
作者
Alunda, Jose Maria [1 ,2 ]
机构
[1] Univ Complutense Madrid, Fac Vet Med, Dept Anim Hlth, Madrid 28040, Spain
[2] Univ Complutense Madrid, Inst Ind Pharm, Fac Pharm, Madrid 28040, Spain
关键词
Trypanosoma; Leishmania; NTD; HAT; AAT; chemotherapy; One Health; resistance; drug targets; drug discovery; CHEMOTHERAPY; RESISTANCE;
D O I
10.3390/microorganisms12010043
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human infections by trypanosomatids are widely distributed and prevalent in the tropical and subtropical regions. Diseases caused by Trypanosoma and Leishmania have variable clinical outcomes, ranging from self-healing to fatality, and are considered Neglected Tropical Diseases (NTD). In addition, animal trypanosomiases have a significant impact on animal health and production, apart from their potential role as reservoirs in zoonotic species. Control of these infections is progressing and, in some cases (such as human African trypanomiasis (HAT)), significant reductions have been achieved. In the absence of effective vaccination, chemotherapy is the most used control method. Unfortunately, the therapeutic arsenal is scarce, old, and of variable efficacy, and reports of resistance to most antiparasitic agents have been published. New drugs, formulations, or combinations are needed to successfully limit the spread and severity of these diseases within a One Health framework. In this Special Issue, contributions regarding the identification and validation of drug targets, underlying mechanisms of action and resistance, and potential new molecules are presented. These research contributions are complemented by an update revision of the current chemotherapy against African Trypanosoma species, and a critical review of the shortcomings of the prevailing model of drug discovery and development.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] The Current Directions of Searching for Antiparasitic Drugs
    Dziduch, Katarzyna
    Greniuk, Dominika
    Wujec, Monika
    MOLECULES, 2022, 27 (05):
  • [42] Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
    Harter, Philipp
    Hilpert, Felix
    Mahner, Sven
    Heitz, Florian
    Pfisterer, Jacobus
    du Bois, Andreas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (01) : 81 - 88
  • [43] New tools for old drugs: Functional genetic screens to optimize current chemotherapy
    Gerhards, Nora M.
    Rottenberg, Sven
    DRUG RESISTANCE UPDATES, 2018, 36 : 30 - 46
  • [44] Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment
    Hattinger, Claudia Maria
    Patrizio, Maria Pia
    Luppi, Silvia
    Magagnoli, Federica
    Picci, Piero
    Serra, Massimo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (04) : 299 - 311
  • [45] Breeding of ornamental orchids with focus on Phalaenopsis: current approaches, tools, and challenges for this century
    Iiyama, Carla Midori
    Vilcherrez-Atoche, Joe Abdul
    Germana, Maria Antonietta
    Vendrame, Wagner Aparecido
    Cardoso, Jean Carlos
    HEREDITY, 2024, 132 (04) : 163 - 178
  • [46] Anthelmintics in the future: current trends in the discovery and development of new drugs against gastrointestinal nematodes
    Zajickova, Marketa
    Linh Thuy Nguyen
    Skalova, Lenka
    Stuchlikova, Lucie Raisova
    Matouskova, Petra
    DRUG DISCOVERY TODAY, 2020, 25 (02) : 430 - 437
  • [47] Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and-2
    Sadowski, Lauren A.
    Upadhyay, Rista
    Greeley, Zachary W.
    Margulies, Barry J.
    VIRUSES-BASEL, 2021, 13 (07):
  • [48] Current issues for anti-malarial drugs to control P-falciparum malaria
    Schellenberg, D
    Abdulla, S
    Roper, C
    CURRENT MOLECULAR MEDICINE, 2006, 6 (02) : 253 - 260
  • [49] Drugs in preclinical and early clinical development for the treatment of Chagas's disease: the current status
    Torchelsen, Fernanda Karoline Vieira da Silva
    Mazzeti, Ana Lia
    Mosqueira, Vanessa Carla Furtado
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (06) : 575 - 590
  • [50] Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment
    Tymon-Rosario, Joan
    Adjei, Naomi N.
    Roque, Dana M.
    Santin, Alessandro D.
    CANCERS, 2021, 13 (24)